AstraZeneca PLC (AZN)
68.52
-0.02
(-0.02%)
USD |
NASDAQ |
Apr 18, 11:06
AstraZeneca Cash from Financing (Quarterly): -291.00M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -291.00M |
| September 30, 2023 | -2.726B |
| June 30, 2023 | -1.519B |
| March 31, 2023 | -2.031B |
| December 31, 2022 | -358.00M |
| September 30, 2022 | -1.43B |
| June 30, 2022 | -1.295B |
| March 31, 2022 | -3.74B |
| December 31, 2021 | -1.051B |
| September 30, 2021 | 142.00M |
| June 30, 2021 | 7.289B |
| March 31, 2021 | -2.731B |
| December 31, 2020 | -2.21B |
| September 30, 2020 | 1.243B |
| June 30, 2020 | 1.126B |
| March 31, 2020 | -2.362B |
| December 31, 2019 | 6.00M |
| September 30, 2019 | -2.712B |
| June 30, 2019 | 1.639B |
| March 31, 2019 | -698.00M |
| December 31, 2018 | -1.732B |
| September 30, 2018 | 169.00M |
| June 30, 2018 | 182.00M |
| March 31, 2018 | -663.00M |
| December 31, 2017 | -12.00M |
| Date | Value |
|---|---|
| September 30, 2017 | -3.07B |
| June 30, 2017 | 2.188B |
| March 31, 2017 | -2.042B |
| December 31, 2016 | -304.00M |
| September 30, 2016 | -1.014B |
| June 30, 2016 | 1.355B |
| March 31, 2016 | -1.361B |
| December 31, 2015 | 4.284B |
| September 30, 2015 | -1.018B |
| June 30, 2015 | 181.00M |
| March 31, 2015 | -2.569B |
| December 31, 2014 | 1.151B |
| September 30, 2014 | -1.286B |
| June 30, 2014 | -358.00M |
| March 31, 2014 | -2.212B |
| December 31, 2013 | 201.00M |
| September 30, 2013 | -1.112B |
| June 30, 2013 | 96.00M |
| March 31, 2013 | -2.232B |
| December 31, 2012 | -525.00M |
| September 30, 2012 | -242.00M |
| June 30, 2012 | -718.00M |
| March 31, 2012 | -3.438B |
| December 31, 2011 | -1.681B |
| September 30, 2011 | -2.85B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.74B
Minimum
Mar 2022
7.289B
Maximum
Jun 2021
-684.79M
Average
-1.295B
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
| GSK PLC | -4.425B |
| Amgen Inc | 2.754B |
| Gilead Sciences Inc | -1.099B |
| Viking Therapeutics Inc | 0.188M |
| Fusion Pharmaceuticals Inc | 57.86M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.38B |
| Cash from Investing (Quarterly) | -1.077B |
| Free Cash Flow | 6.567B |
| Free Cash Flow Per Share (Quarterly) | 0.4573 |
| Free Cash Flow to Equity (Quarterly) | 1.537B |
| Free Cash Flow to Firm (Quarterly) | 1.801B |
| Free Cash Flow Yield | 3.07% |